Literature DB >> 19604480

Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.

Sylvia R Luckner1, Carl A Machutta, Peter J Tonge, Caroline Kisker.   

Abstract

Mycobacteria have a unique cell wall consisting of mycolic acids, very-long-chain lipids that provide protection and allow the bacteria to persist within human macrophages. Inhibition of cell wall biosynthesis is fatal for the organism and a starting point for the discovery and development of novel antibiotics. We determined the crystal structures of KasA, a key enzyme involved in the biosynthesis of long-chain fatty acids, in its apo-form and bound to the natural product inhibitor thiolactomycin. Detailed insights into the interaction of the inhibitor with KasA and the identification of a polyethylene glycol molecule that mimics a fatty acid substrate of approximately 40 carbon atoms length, represent the first atomic view of a mycobacterial enzyme involved in the synthesis of long-chain fatty acids and provide a robust platform for the development of novel thiolactomycin analogs with high affinity for KasA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604480      PMCID: PMC2734888          DOI: 10.1016/j.str.2009.04.012

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  42 in total

1.  Worldwide incidence of multidrug-resistant tuberculosis.

Authors:  Christopher Dye; Marcos A Espinal; Catherine J Watt; Cyrille Mbiaga; Brian G Williams
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

2.  Separate entrance and exit portals for ligand traffic in Mycobacterium tuberculosis FabH.

Authors:  Sarbjot Sachdeva; Faik N Musayev; Mamoun M Alhamadsheh; J Neel Scarsdale; H Tonie Wright; Kevin A Reynolds
Journal:  Chem Biol       Date:  2008-04

3.  Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism.

Authors:  A C Price; K H Choi; R J Heath; Z Li; S W White; C O Rock
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

Review 4.  PEGylation, successful approach to drug delivery.

Authors:  Francesco M Veronese; Gianfranco Pasut
Journal:  Drug Discov Today       Date:  2005-11-01       Impact factor: 7.851

5.  Platensimycin is a selective FabF inhibitor with potent antibiotic properties.

Authors:  Jun Wang; Stephen M Soisson; Katherine Young; Wesley Shoop; Srinivas Kodali; Andrew Galgoci; Ronald Painter; Gopalakrishnan Parthasarathy; Yui S Tang; Richard Cummings; Sookhee Ha; Karen Dorso; Mary Motyl; Hiranthi Jayasuriya; John Ondeyka; Kithsiri Herath; Chaowei Zhang; Lorraine Hernandez; John Allocco; Angela Basilio; José R Tormo; Olga Genilloud; Francisca Vicente; Fernando Pelaez; Lawrence Colwell; Sang Ho Lee; Bruce Michael; Thomas Felcetto; Charles Gill; Lynn L Silver; Jeffery D Hermes; Ken Bartizal; John Barrett; Dennis Schmatz; Joseph W Becker; Doris Cully; Sheo B Singh
Journal:  Nature       Date:  2006-05-18       Impact factor: 49.962

6.  Protein-protein interactions within the Fatty Acid Synthase-II system of Mycobacterium tuberculosis are essential for mycobacterial viability.

Authors:  Romain Veyron-Churlet; Olivier Guerrini; Lionel Mourey; Mamadou Daffé; Didier Zerbib
Journal:  Mol Microbiol       Date:  2004-12       Impact factor: 3.501

7.  Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.

Authors:  R A Slayden; R E Lee; J W Armour; A M Cooper; I M Orme; P J Brennan; G S Besra
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB.

Authors:  M L Schaeffer; G Agnihotri; C Volker; H Kallender; P J Brennan; J T Lonsdale
Journal:  J Biol Chem       Date:  2001-10-12       Impact factor: 5.157

Review 9.  Extensively drug-resistant tuberculosis: current challenges and threats.

Authors:  Amita Jain; Rajesh Mondal
Journal:  FEMS Immunol Med Microbiol       Date:  2008-05-08

10.  CAVER: a new tool to explore routes from protein clefts, pockets and cavities.

Authors:  Martin Petrek; Michal Otyepka; Pavel Banás; Pavlína Kosinová; Jaroslav Koca; Jirí Damborský
Journal:  BMC Bioinformatics       Date:  2006-06-22       Impact factor: 3.169

View more
  26 in total

1.  Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design.

Authors:  Benjamin Schaefer; Caroline Kisker; Christoph A Sotriffer
Journal:  J Comput Aided Mol Des       Date:  2011-11-11       Impact factor: 3.686

2.  Structural and functional conservation of Mycobacterium tuberculosis GroEL paralogs suggests that GroEL1 Is a chaperonin.

Authors:  Bernhard Sielaff; Ki Seog Lee; Francis T F Tsai
Journal:  J Mol Biol       Date:  2010-11-19       Impact factor: 5.469

3.  Elucidation of the protonation states of the catalytic residues in mtKasA: implications for inhibitor design.

Authors:  Wook Lee; Sylvia R Luckner; Caroline Kisker; Peter J Tonge; Bernd Engels
Journal:  Biochemistry       Date:  2011-06-07       Impact factor: 3.162

4.  Structural Basis for the Regulation of the MmpL Transporters of Mycobacterium tuberculosis.

Authors:  Jared A Delmar; Tsung-Han Chou; Catherine C Wright; Meredith H Licon; Julia K Doh; Abhijith Radhakrishnan; Nitin Kumar; Hsiang-Ting Lei; Jani Reddy Bolla; Kanagalaghatta R Rajashankar; Chih-Chia Su; Georgiana E Purdy; Edward W Yu
Journal:  J Biol Chem       Date:  2015-09-22       Impact factor: 5.157

5.  Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.

Authors:  Carl A Machutta; Gopal R Bommineni; Sylvia R Luckner; Kanishk Kapilashrami; Bela Ruzsicska; Carlos Simmerling; Caroline Kisker; Peter J Tonge
Journal:  J Biol Chem       Date:  2009-12-16       Impact factor: 5.157

6.  Thiolactomycin-Based Inhibitors of Bacterial β-Ketoacyl-ACP Synthases with in Vivo Activity.

Authors:  Gopal R Bommineni; Kanishk Kapilashrami; Jason E Cummings; Yang Lu; Susan E Knudson; Chendi Gu; Stephen G Walker; Richard A Slayden; Peter J Tonge
Journal:  J Med Chem       Date:  2016-05-24       Impact factor: 7.446

7.  A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.

Authors:  Daigo Inoyama; Divya Awasthi; Glenn C Capodagli; Kholiswa Tsotetsi; Paridhi Sukheja; Matthew Zimmerman; Shao-Gang Li; Ravindra Jadhav; Riccardo Russo; Xin Wang; Courtney Grady; Todd Richmann; Riju Shrestha; Liping Li; Yong-Mo Ahn; Hsin Pin Ho Liang; Marizel Mina; Steven Park; David S Perlin; Nancy Connell; Véronique Dartois; David Alland; Matthew B Neiditch; Pradeep Kumar; Joel S Freundlich
Journal:  Cell Chem Biol       Date:  2020-03-19       Impact factor: 8.116

8.  Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis.

Authors:  Johannes Schiebel; Kanishk Kapilashrami; Agnes Fekete; Gopal R Bommineni; Christin M Schaefer; Martin J Mueller; Peter J Tonge; Caroline Kisker
Journal:  J Biol Chem       Date:  2013-10-09       Impact factor: 5.157

9.  Thiolactomycin-based β-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy.

Authors:  Kanishk Kapilashrami; Gopal R Bommineni; Carl A Machutta; Pilho Kim; Cheng-Tsung Lai; Carlos Simmerling; Francis Picart; Peter J Tonge
Journal:  J Biol Chem       Date:  2013-01-10       Impact factor: 5.157

Review 10.  Production of recombinant proteins in Mycobacterium smegmatis for structural and functional studies.

Authors:  Ghader Bashiri; Edward N Baker
Journal:  Protein Sci       Date:  2014-11-13       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.